KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Short term Debt (2016 - 2025)

Abbott Laboratories (ABT) has disclosed Short term Debt for 17 consecutive years, with $3.0 billion as the latest value for Q4 2025.

  • Quarterly Short term Debt rose 102.2% to $3.0 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.0 billion through Dec 2025, up 102.2% year-over-year, with the annual reading at $3.0 billion for FY2025, 102.2% up from the prior year.
  • Short term Debt hit $3.0 billion in Q4 2025 for Abbott Laboratories, up from $1.3 billion in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $3.0 billion in Q4 2025 to a low of $4.0 million in Q1 2022.
  • Historically, Short term Debt has averaged $1.3 billion across 5 years, with a median of $1.1 billion in 2022.
  • Biggest five-year swings in Short term Debt: crashed 99.47% in 2022 and later soared 57025.0% in 2023.
  • Year by year, Short term Debt stood at $754.0 million in 2021, then skyrocketed by 198.54% to $2.3 billion in 2022, then plummeted by 52.02% to $1.1 billion in 2023, then surged by 38.89% to $1.5 billion in 2024, then skyrocketed by 102.2% to $3.0 billion in 2025.
  • Business Quant data shows Short term Debt for ABT at $3.0 billion in Q4 2025, $1.3 billion in Q3 2025, and $507.0 million in Q2 2025.